Skip to main content
Orchid Pharma Limited logo

Orchid Pharma Limited — Investor Relations & Filings

Ticker · ORCHPHARMA ISIN · INE191A01027 LEI · 33580076KIKCYSLZVF05 BSE.NS Manufacturing
Open in API
Filings indexed 451 across all filing types
Latest filing 2022-09-23 Regulatory Filings
Country IN India
Listing BSE.NS ORCHPHARMA

About Orchid Pharma Limited

https://www.orchidpharma.com/

Orchid Pharma Limited is a vertically integrated organization focused on the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company specializes in the anti-infectives segment, with a particular emphasis on cephalosporins and penicillins. Its operations span the entire value chain, including advanced research and development, process chemistry, and large-scale manufacturing. Orchid Pharma maintains facilities that adhere to rigorous international regulatory standards, enabling the supply of high-quality generic formulations and complex molecules to global markets. The company prioritizes innovation in chemical synthesis and formulation development to address complex therapeutic requirements and enhance healthcare outcomes through a robust portfolio of essential medicines.

Recent filings

Filing Released Lang Actions
General updates
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the dismissal of an application for a Scheme of Amalgamation and Arrangement by the National Company Law Tribunal (NCLT). It is a regulatory announcement informing the stock exchanges about a legal proceeding outcome related to a merger proposal. The document is short (1835 characters) and serves as a notification rather than a detailed merger filing or full report. It does not contain detailed financial data or merger documentation but rather an update on the status of a merger-related legal matter. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not neatly fit into more specific categories like M&A Activity or Merger & Acquisition filings, which would typically include detailed merger documents or proposals.
2022-09-23 English
Transcript of Analysts/Institutional Investor Meet/Con. Call
Call Transcript Classification · 100% confidence The document is a transcript of an earnings conference call held on August 10, 2022, discussing the financial results for the quarter ended June 30, 2022 (Q1 FY23). It includes detailed management commentary, financial highlights, business updates, and Q&A with analysts. The text explicitly mentions it is a transcript of the Q1 FY23 earnings conference call, which matches the definition of a Call Transcript (CT). The document is about 15,000 characters long and contains the full text of the call, not just an announcement or summary. Therefore, it should be classified as a Call Transcript (CT).
2022-08-17 English
Newspaper Advertisements
Interim / Quarterly Report Classification · 95% confidence The document is a communication addressed to stock exchanges (NSE and BSE) regarding the publication of unaudited standalone and consolidated financial results for the quarter ended June 30, 2022. It references Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates the publication of quarterly financial results. The document includes newspaper publication copies of these financial results. The key indicators are: 'Unaudited Standalone & Consolidated Financial Results for the quarter ended June 30, 2022', and the mention of quarterly results publication. The document is not the full financial report itself but a notification and evidence of publication of the quarterly financial results. However, the document length is 15,000 characters, which is substantial, and it contains the actual financial results data (as indicated by the mention of standalone and consolidated results and detailed financial figures). Therefore, this is the actual Interim / Quarterly Report (IR) filing, not just an announcement or a brief notice. Hence, the correct classification is Interim / Quarterly Report (IR). Q1 2023
2022-08-11 English
Recording of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a short communication dated August 10, 2022, addressed to stock exchanges, providing a link to the audio recording of an analysts/investors call regarding the financial results for the quarter ended June 30, 2022. It references the approval of the results by the Board but does not contain any financial data or detailed transcript itself. The document is essentially an announcement of the availability of the call recording, not the call transcript or financial report itself. Given the short length (1363 characters) and the nature of the content, this fits best as a Regulatory Filing (RNS) since it is a regulatory announcement about the call recording rather than the full transcript or report.
2022-08-10 English
Investor Presentation
Regulatory Filings
2022-08-10 English
Outcome of Board Meeting
Regulatory Filings
2022-08-10 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.